This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Cellectis Presents Positive CAR-T Trial Data
Tech clinical trial results

Cellectis Presents Positive CAR-T Trial Data

Analysis based on 7 articles · First reported Jun 11, 2026 · Last updated Jun 11, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive Phase 1 results for lasme-cel and eti-cel from Cellectis are likely to positively impact the stock price of Cellectis, as these therapies show promise for difficult-to-treat cancers. This could also attract further investment in the biotechnology sector, particularly in gene-editing and CAR-T therapies.

Biotechnology Pharmaceuticals
Event Summary

Cellectis, a clinical-stage biotechnology company, presented final Phase 1 data for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and preliminary data for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) at the European Hematology Association (EHA) 2026 Annual Congress. The BALLI-01 trial for lasme-cel showed a 100% overall response rate and a manageable safety profile, with 75% of responders achieving minimal residual disease negative status. Nitin Jain, M.D., from the MD Anderson Cancer Center, highlighted the significance of these results for patients with limited treatment options. The NATHALI-01 trial for eti-cel demonstrated an 88% overall response rate and a 63% complete response rate in the optimal dose cohort, with Professor Emmanuel Bachy, M.D., Ph.D., from Hospices Civils de Lyon, noting the positive correlation between alemtuzumab exposure and clinical outcomes. Both trials are open for further recruitment, with interim analysis for BALLI-01 expected in Q4 2026 and full Phase 1 data for NATHALI-01 also expected in Q4 2026.

Entities Involved
stock
Cellectis
Cellectis presented positive Phase 1 data for its CAR-T therapies, lasme-cel and eti-cel, which could lead to accelerated development and increased investor confidence.
Importance 100.0 Sentiment 70.0
per
Emmanuel Bachy
Professor Emmanuel Bachy, M.D., Ph.D., presented preliminary data for eti-cel, emphasizing the potential of optimizing alemtuzumab exposure for better CAR-T expansion.
Importance 70.0 Sentiment 20.0
per
Nitin Jain
Nitin Jain, M.D., presented the final Phase 1 data for lasme-cel, highlighting its promising results for patients with limited treatment options.
Importance 70.0 Sentiment 20.0
oth
Hospices Civils de Lyon
Hospices Civils de Lyon is where Professor Emmanuel Bachy, M.D., Ph.D., is affiliated and where the NATHALI-01 trial data was presented.
Importance 30.0 Sentiment 0.0
ngo
European Hematology Association
Cellectis presented its clinical trial data at the European Hematology Association (EHA) 2026 Annual Congress.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.